Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual

Canadian Cancer Trials Group IND.183 -- A Phase II Study of Sunitinib in Patients with Advanced Malignant Pleural Mesothelioma -- was closed to accrual on 10 September 2010.